The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 13, 2018
Filed:
Nov. 24, 2014
Applicant:
Chemocentryx, Inc., Mountain View, CA (US);
Inventors:
Solomon Ungashe, Fremont, CA (US);
John J. Wright, Redwood City, CA (US);
Andrew Pennell, San Francisco, CA (US);
Zheng Wei, Union City, CA (US);
Anita Melikian, Mountain View, CA (US);
Assignee:
ChemoCentryx, Inc., Mountain View, CA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 417/12 (2006.01); C07D 213/26 (2006.01); C07D 213/50 (2006.01); C07D 213/52 (2006.01); C07D 213/70 (2006.01); C07D 213/74 (2006.01); C07D 213/84 (2006.01); C07D 213/89 (2006.01); C07D 241/12 (2006.01); C07D 405/12 (2006.01); C07D 413/12 (2006.01); A61K 31/4409 (2006.01); A61K 31/443 (2006.01); A61K 31/4439 (2006.01); A61K 31/4545 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01); A61K 45/06 (2006.01); C07D 239/26 (2006.01); C07D 401/12 (2006.01); C07D 409/12 (2006.01);
U.S. Cl.
CPC ...
C07D 417/12 (2013.01); A61K 31/443 (2013.01); A61K 31/4409 (2013.01); A61K 31/4439 (2013.01); A61K 31/4545 (2013.01); A61K 31/496 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61K 45/06 (2013.01); C07D 213/26 (2013.01); C07D 213/50 (2013.01); C07D 213/52 (2013.01); C07D 213/70 (2013.01); C07D 213/74 (2013.01); C07D 213/84 (2013.01); C07D 213/89 (2013.01); C07D 239/26 (2013.01); C07D 241/12 (2013.01); C07D 401/12 (2013.01); C07D 405/12 (2013.01); C07D 409/12 (2013.01); C07D 413/12 (2013.01);
Abstract
Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.